Post-acute or prolonged COVID-19: ivermectin treatment for patients with persistent symptoms or post-acute symptoms
Chang et al., ResearchGate (Preprint)
Chang et al., Post-acute or prolonged COVID-19: ivermectin treatment for patients with persistent symptoms or post-acute.., ResearchGate (Preprint)
Report on 33 patients with persistent or post-acute symptoms treated with ivermectin, showing a high rate of clinical improvement.
Chang et al., 31 Jul 2020, preprint, 4 authors.
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/344318845
POST-ACUTE OR PROLONGED COVID-19: IVERMECTIN TREATMENT FOR
PATIENTS WITH PERSISTENT SYMPTOMS OR POST-ACUTE
Preprint · July 2020
5 authors, including:
Gustavo Aguirre Chang
National University of San Marcos
Instituto Nacional de Oftalmología - Peru
118 PUBLICATIONS 82 CITATIONS
4 PUBLICATIONS 3 CITATIONS
Aurora Natividad Trujillo Figueredo
José Aníbal Córdova Masías
Instituto nacional de ciencias Neurológicas, Lima, Perú
107 PUBLICATIONS 23 CITATIONS
11 PUBLICATIONS 18 CITATIONS
Some of the authors of this publication are also working on these related projects:
COVID 19 View project
COVID POR VARIANTES DEL SARS COV-2 View project
All content following this page was uploaded by Gustavo Aguirre Chang on 22 October 2020.
The user has requested enhancement of the
POST-ACUTE OR PROLONGED COVID-19: TREATMENT WITH
IVERMECTIN FOR PATIENTS WITH PERSISTENT, OR POST-ACUTE
Aguirre-Chang, Gustavo; Castillo Saavedra, Eduardo; Yui Cerna, Manuel;
Trujillo Figueredo, Aurora; Córdova Masías, José. Reseach Gate. July 11, 2020.
English translation copy edited by Madeline Oh
INTRODUCTION: It is estimated that between 10 to 45% of people who become ill with
COVID-19 will present with symptoms after the acute stage of the disease. These
symptoms will persist for weeks, developing what is called Persistent or Post-Acute
Symptoms of COVID- 19. There is no consensus, nor has there been a publication on
specific and effective treatment for these cases. Knowledge is quite lacking as to its
MATERIAL AND METHODS: 33 patients with Persistent or Post-Acute Symptoms of
COVID-19, who were between weeks 4 and 12 from the onset of symptoms were enrolled
in the present study. Patients whose main symptoms were musculoskeletal such as
fatigue due to muscle weakness, diminished muscle strength and myalgia (muscle pain)
were excluded. The following protocol was followed: in cases with mild symptoms,
Ivermectin was administered at a dose of 0.2 mg per kilogram of body weight per day for
2 days. If patients still had symptoms after the 2 doses, 2 additional days of Ivermectin
treatment were given at the same dose. For cases with moderate symptoms, a dose of
0.4 mg per kilogram of body weight was prescribed for 2 days, followed by 0.2 mg per
kilogram of body weight for 2 additional days. If a patient continued to have symptoms
after the fourth day of treatment, more doses of Ivermectin were indicated. Treatment
then continued for additional days until either clinical improvement was observed, or there
was no longer further clinical improvement with treatment.
RESULTS: 33 adult patients with Persistent or Post-Acute Symptoms of COVID-19 were
treated with Ivermectin. In 94% of the 33 patients, clinical improvement to some degree
(partial or total) was observed after 2 doses of Ivermectin. Total improvement (without
any symptoms) was observed in 87.9% of the patients after the 2 daily doses of
Ivermectin. In 12.1% of patients whose symptoms had not been completely resolved after
the first 2 doses, additional doses of Ivermectin treatment were administered according
to the protocol, and total clinical resolution of symptoms was observed in 94% of cases.
CONCLUSION: The result of the present study..
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC
provide treatment protocols.